Yuhido

Yuhido is a biotechnology company dedicated to pioneering the next generation of extracellular vesicle (EV) therapeutics. The company's proprietary platform focuses on the precise engineering of EVs to enable the targeted delivery of diverse therapeutic modalities, including proteins and RNA, which have historically been difficult to deliver. By optimizing vesicle loading and surface engineering, Yuhido seeks to address critical limitations in current drug delivery technologies, such as tissue specificity and immune evasion. The company is primarily targeting applications in oncology and rare genetic diseases where conventional therapies are insufficient. Founded by Nobel laureate Randy Schekman and supported by top-tier venture capital, Yuhido is positioned at the forefront of vesicle-mediated medicine.